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Five antiarrhythmic drugs (bretylium, clofilium, propranolol, N-acetylprocainamide and amiodarone) were tested for their ability to modify 
phospholipid metabolism in Jurkat T lymphocytes. The five drugs, dccmaz~ in a dose-dependent mode the biosynthesis of both phosphati- 
dylcholine and phosphatidylethanolamine, this effect was essentially due to impairment of either choline or ethanolmnine uptake by the cells. The 
efficiency of the drugs to inhibit phosphatidylcholine and phosphatidylethanolamine sy thesis was in the order: clofilium ~, amiodarone 
propranolol =bretylium ~ N.acetylproeainamide. The ICso varied from 3-5 #M for clofilium to >200/tM for N-acetyiprocainamide. In contrast, 
only elofilium, a voltage-gated K*-channel blocker, was able to increase phosphatidyls¢rine synthesis with an ECs = 50/aM. The effect ofclofilium 
on phosphatidylserine synthesis thus mimics the effect of three other K÷-channel blockers, quinine, 4-aminopyridine and tetraethylammonium, 
su~esting close relationships between phosphatidylserine synthesis and K* channel activity. 
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1. INTRODUCTION 
Cationic amphiphilic drugs, such as antiarrhythmics 
are known to modify phospholipid metabolism [1]. 
Amiodarone, for example, has been shown to inhibit 
choline uptake and phosphatidylcholine (PtdCho) bio- 
synthesis in cardiac myocytes [2]. These metabolic ef- 
fects of amiodarone raise the question whether the effect 
on choline uptake could be implicated in some amiodar- 
one's electrophysiologic or toxic effects, As discussed by 
Rabkin [2], the amiodarone-induced reduction in 
choline uptake may modulate the outward potassium 
current in myocytes. On the other hand, we have shown 
in previous reports [3,4], that in Jurkat T lymphocytes 
and in the monocytic cell line, THPI, the blockers of 
voltage-dependent potassium channels uch as quinine, 
4-aminopyridine and tetraethylammonium strongly 
modify phospholipid metabolism. Phosphatidylcholine 
(PtdCho) and phosphatidylethanolamine (PtdEtn) syn- 
thesis were inhibited because K+-channel blockers in- 
hibited both choline and ethanolamine uptake by the 
cells. An effect very similar to that described for ami- 
odarone [2]. In addition, K+-channcl blockers increased 
strongly phosphatidylserine (PtdSe0 synthesis in Jurkat 
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T cells. Since some antiarrhythmie drugs have been de- 
scribed to block voltage-gated K" channels and since 
Jurkat cells express this type of channel, it was of inter- 
est to see whether antiarrhythmic drugs affect phospho- 
lipid metabolism in T lymphoeytes. The results pre- 
sented show that the five antiarrhythmic drags test~i 
decrease PtdCho and PtdEtn synthesis. By contrast, 
only clofilium, a voltage-dependent K"-channel 
blocker, was able to increase in a concentration-depend- 
ent mode the biosynthesis of PtdSer. 
2. MATERIALS AND METHODS 
2.1. Cells 
durkat D: the human T cell line Jurkat was kindly supplied by Dr. 
A.M. Schmitt-~erhulst (Centre d'Immunologie, Marseille-Luminy, 
France). C~lls were cloned by limiting dilution and clone D wa~ sc- 
le.cted on the basis of its IL-2 production when activated with either 
PHA, CD3 or CD2 mAbs in the presence of the phorbolester (TPA). 
Cells were cultured in RPMI 1640 (Seromed, Lille, France) supple. 
mented with 5% fetal calf serum, 2 mM t.-glammine, 1mM pyruvate. 
2.2. Chemicals 
Amiodarone hydrochloride was purchased from Sigma Chemical 
Co. (La Verpill~re, France). N-Acetylproeainamide hydroehloride 
(NAPA), clofilium tozylat¢ and bretylium tosylate were from RBI 
(Natick, MA, USA), Fropranolol was from Aldrich (Straslmarg, 
France). [l-~H]Ethan-l-ol-2-amine hydrochloride (1.85-2.2 GBq/ 
mmol), [,nethyl-'~H]chotinc chloride (2.8-3.1 GBqfmmol) and 
[~H]serine (0.37-1 TBq/mrnol) were purchased from Amersham (Les 
Ulis, France). 
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2.3. Pho~pholipM synthesis 
Jurkat cells (2 × 106) were maintained in0.5 ml of a buffer (pH 7.4) 
containing 137 mM NaCI, 2.7 mM KCI, 1 mM Na:HPO 4, 2.5 mM 
glucose, 20 mM HEPES, 0.1% bovine serum albumin, 1 mM CaCl, 
and 1 mM MgCI:, at 37"C in the presence of the tritiated precursors 
for phospholipid synthesis and elTectors (see concentrations in the 
figure legends). After a 3 h incubation period the cells were rapidly 
sedimented and washed in an Eppendorf centrifuge, the supernatants 
were discarded and the cell phospholipids were extracted using chloro- 
form/methanol/water according to Bligh and Dyer [5]. This two-step 
extraction procedure allowed the determination f total tall]products 
incorporated into the c~lis, by measuring radioactivity on a 50 #1 
sample of the chloroform/methanol extract. For this purpose, the 50 
/al sampl~ was mixed with 3 ml of Picofluor.30 (Packard, Rungis, 
Frano~) and radioactivity was determined by scintillation with a Kon- 
tron ,dmatic counter. Then the addition of chloroform and water 
allowed the separation of the organic and aqueous phases. The lipid 
extracts (organic phases) were analyzed by thin-layer chromatography 
on LK6D plates (Whatman) in a solvent system composed ofehloro- 
form/methanol/acetic acid/water (75:45:12:3). Authentic phospholip- 
ids standards (Sigma Chemicals, St. Louis. MO) were run in parallel 
and detected with iodide vapors. Radioactivity on TLC plates was 
quantified by using an automatic linear radiochromatography ana- 
lyzer (Berthold) equipped with a 8 mm window. 
3. RESULTS 
3.1. Choline uptake and PtdCho synthesis 
Measurements of total [~H]choline uptake and of 
[~l-1]choline incorporation i to PtdCho in lurkat T cells 
in the presence of various amounts of either amiodar- 
one, NAPA, clofilium, propranolol or bretylium are 
depicted in Fig. 1. The five drugs induced a concentra- 
tion-dependent decrease of [3H]choline uptake by the 
cells and consequently induced a dose-dependent de- 
crease of PtdCho synthesis as measured by the incorpo- 
ration of [3H]choline into this phospholipid. 
3.2. Ethanolamine uptake and PtdEtn synthesis 
Since in our previous reports [3,4] we have shown that 
K~-channel blockers had similar effects on both 
choline- and ethanolamine-containing phospholipids, 
we have also studied the effect of the five above-men- 
tioned drugs on [3H]ethanolamine uptake and [3H]etha- 
nolamine incorporation i to PtdEtn. As shown in Fig. 
2, all the drugs studied decreased both [~H]ethanol- 
amine uptake and PtdEtn synthesis. The IC~0 (Tab!e I) 
indicated that the drugs studied inhibited both the up- 
take of the phospholipid polar head groups and phos- 
pholipid synthesis in the following order: clofilium > 
amiodarone >> propranolol = bretylium >> NAPA. 
3.3. PtdSer synthesis 
Previous results [3,4] indicated that K*-channel 
blockers such as quinine, 4-aminopyridine and tetra- 
ethylammonium were able to increase PtdSer synthesis 
in absence of significant changes in the uptake of 
[SH]serine into the cells. In order to verify the specificity 
of this unexpected result, we measured PtdSer synthesis 
in the presence of either amiodarone, NAPA, clofilium0 
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Fig. 1. Effect of antiarrhythmic dru~s on [~H]choline uptake (A) and 
phosphatidylcholine synthesis (B) in Jurkat T lymphocytes. Cells were 
incubated in the presence of 4 #Ci [~H]cholin¢ for 2 h then treated as 
described in s~tion 2, Results are enprcssed as % versus untreated 
cells, (~) Clofilium; (B) amiodarone; (o) bmtylium; (o) propranolol; 
and (o) N-acetylprocainamide. 
propranolol and bretylium. As shown in Fig. 3, only 
clofilium was able to increase PtdSer synthesis n a dose- 
dependent mode with an ECs0 = 50 #M. The 4 other 
dnigs, amiodaron¢, NAPA, propranolol and bretylium0 
tested at concentrations up to 200/zM, had no signifi- 
cant effect on either [~H]serine uptake or PtdSer synthe- 
sis (Fig. 3). In the above experiments PtdSer synthesis 
was measured after a 3 h incubation period; it was thus 
of interest o study the kinetic of PtdSer synthesis in 
control and K+-channel blocker-treated cells. As shown 
in Fig. 4, PtdSer synthesis was measured from 0 to 60 
rain, and clofilium at 100 #M rapidly increased PtdSer 
Table I 
Effeetors Cho uptake PtdCho Etn uptake PtdEtn 
(/zM) (/aM) (/zM) (uM) 
CIofilium 5,0 2.9 2,8 3.7 
Amiodarone 11,3 34.4 9,7 16,8 
Propranolol 100 105 100 90 
Bretylium 130 100 111 95 
NAPA >200 >200 >200 >200 
ICso for the inhibition of[~H]cholinc uptake (Cho uptake), phosphat- 
idylcholin~ synthesis (PtdCho), [3H]ethanolamine uptake (Etn uptake) 
and phosphatidylethanolamine sy thesis (PtdEtn) by antiarrhythmic 
drugs, Each value represents he mean of duplicate determinations 
calculated from the curves in Figs. 1 and 2, 
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Fig, 2, Ef f~t ofantiarrhythmie drugs on [~H]ethanolamine uptake (A) 
and phosphatidylethanolamine synthesis (B) in Jurkat T cells. Ceils 
were incubated as described in the legend of Fig. 1 but in the presence 
of 4 ~Ci [~H]ethanolarnine, Results are expressed as % versus un- 
treat~l cells. (=) Clofilium; (11) arnivdarone; (e) bmtylium; (<3) propra- 
nolol; and (o) N-acetylproeainamide. 
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Fig. 3. Effect of antiarrhythmic drugs on [~H]s~rine uptake and 
phosphatidyl~rine synthesis n Jurkat T lymphocyt~s, Cells were incu- 
bated for 2 h in the pr~nce  of 4 ,uCi [~H]scrin¢. Other details as in 
section 2. (ta) Clofilium; (s) amiodarone; (e) brctylium; (o) propta- 
nolol; and (¢) N-acetylprocainamide. 
synthesis. The differences between the points for control 
and clofilium-treated cells were l~ighly significant (P < 
0.05, n = 6) after 15 rain of treatment. 
3.4. Metabolism of PtdSer into PtdEtn by decarboxyla- 
tion 
In Jurkat cells [6], a portion of PtdSer is converted 
into PtdEtn by decarboxylation; we have thus studied 
this pathway in the presence of 100/,tM of the different 
drugs. The results obtained indicated that clofilium, at 
this concentration, strongly raised PtdSer synthesis 
(5593 + 161 cpm vs. 2622 +_ 97 cpm for controls), while 
bretylium, amiodarone, propranolol and NAPA caused 
less than 15% change. Concomitantly, the incorpora- 
tion of [~H]serine into PtdEtn resulting from decarbox- 
ylation of ~H-labelled PtdSer was measured and ap- 
peared non-significantly changed in the presence of 
elofilium (326 __. 17 cpm vs. 297 +_ 27 cpm for untreated 
cells). The four other drugs were also without significant 
effect (less than 10% change). 
4. DISCUSSION 
Antiarrhythmic drugs such as amiodarone or propra- 
. 1 1 ~..i,..~,, ,h,, f~ma,.,ofcationieamphiphilicdrugs. , ,O ,O ,  ,~ , , . , , ,  SO . . . . . . . . . .  ,, 
Although these drugs have been found extremely efl'ec- 
tire in the treatment of various cardiac arrhythrr:ias, 
one limiting factor to their use is their toxicity. Alter- 
ation of phospholipid metabolism by cationic am- 
phiphilic drugs has been recently reviewed [1], Recent 
results obtained by Rabkin [2] have shown that ami- 
odarone inhibits choline uptake and as a consequence 
PtdCho synthesis n cultured chick cardiac myocytes. In 
the present report, we confirm the results obtained by 
Rabkin on the effect of amiodarone on PtdCho synthe- 
sis and we extend these results to other antiarrhythmic 
drugs and to PtdEtn synthesis n different cells. Indeed, 
we have tested the effect of five antiarrh~hmic drugs on 
PtdCho, PtdEtn and PtdSer metabolism in the Jurkat 
T cell line, The results obtained clearly indicate that all 
antiarrhythmic drugs tested decreased PtdCho and 
PtdEtn synthesis in a dose-dependent mode. This effect 
appears mainly due to a decreased uptake of the triti- 
ated phospholipid polar head groups by the cells. Struc- 
tural relationships between choline/¢thanolamine and 
the antiarrhythmic drugs tested (all the drugs tested 
contain an ammonium group) might be the cause for the 
decreased uptake of choline and ethanolamine by the 
cells. 
Results obtained when studying phosphatidylserine 
synthesis how that only clofilium is able to stimulate 
the synthesis of this phospholipid. Similar results have 
been previously observed [3,4] in cells treated with well- 
known K*-channel blockers uch as quinine, quinidine, 
4-aminopyr~din~ and tetraethylammonium, Since clofil. 
ium has been previously shown to block voltage-gated 
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Fig. 4. Kinetics of clofilium.induced phosphatidylserine synthesis in 
Jarkat T ceils. Results are expressed incpm of ['~H]scrine incorporated 
into phosphatidylserine m asured after thin-layer chromatography of 
phospholipid extracts. Each point is the mean __. SD of two experi- 
ments each done in triplicate. (o) Control cells; and (0) clofilium- 
treated cells. 
K+-channel [7] and since this type of channel has been 
demonstrated to be the major K+-channel xpressed by 
T lymphocytes [8-10], including Jurkat T cells [3], it 
could be hypothesized that ¢lofilium blocks K+-channel 
in T cells. The mechanism of K+-channel-blocker-in- 
duced PtdSer synthesis remains unknown. In T cells, as 
in other cells, PtdSer is synthesized by an exchange of 
polar head group with preexisting phospholipids such 
as PtdCho and PtdEtn [11]. The base exchange nzyme 
system is activated by Ca ~-÷ ions and is energy independ- 
ent [12,13]. A change in Ca 2+ induced by K*-ehannel 
blockers in Jurkat cells appears unlikely to explain the 
enhanced synthesis of PtdSer since we have shown (un- 
published results) that K*-channel blockers including 
quinine, quinidine and clofilium had no effect on intra- 
cellular Ca'-* concentration a d does not affect changes 
in [Ca""]t induced by the classical T cell activators uch 
as phytohaemagglutinin andmonoclonal antibedies di- 
rected against he T cell receptor complex such as CD3. 
On the other hand, the stimulation of PtdSer synthesis 
is not due to a consequence of the inhibition of either 
PtdCho or PtdEtn synthesis since the other antiarrhyth- 
mie drugs have no effect on PtdSer and since we have 
previously shown that inhibitors of choline transport 
such as hemicholinium-3, decamethonium and do- 
deeyltrimethyl ammonium strongly decreased PtdCho 
and PtdEtn synthesis but had no effect on PtdSer [4]. 
The strong and rapid changes observed in phospholipid 
metabolism ay shed a new light on some side-effects 
of antiarrhythmic drugs but further work is necessary 
to elucidate the mechanism leading to activation of 
PtdSer synthesis by K+-channel blockers. In addition, 
complex relationships between K+-¢hannel activity and 
PtdSer might exist since it has been shown that the 
ability of aminopyridines to block K*-channels corre- 
lates with their potencies to bind to PtdSer membranes 
[14]. On the other hand, it has been shown [15] that the 
binding domain of aminopyridines at the intracellular 
face of the K+-channel has characteristics similar to that 
of the PtdSer head group. 
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